约 26,700 个结果
在新选项卡中打开链接
  1. The Lancet
    https://www.thelancet.com › journals › lan…

    MOR202, a novel anti-CD38 monoclonal …

    MOR202, a human anti-CD38 monoclonal antibody, mediates potent tumoricidal activity in vivo and shows synergistic …

    • 作者: Marc S Raab, Monika Engelhardt, Antje Blank, Hartmut Goldschmidt, Hermine Agis, Igor W Blau, Hermann...
    • Publish Year: 2020
  2. American Society of Hematology
    https://ashpublications.org › blood › article

    MOR202, a Human Anti-CD38 Monoclonal Antibody, …

    2015年12月3日 · Background: MOR202, a human anti-CD38 monoclonal antibody, is currently being evaluated in a phase I/IIa clinical trial for the …

    • 作者: Rainer Boxhammer, Johannes Weirather, Stefan Steidl, Jan Endell
    • Publish Year: 2015
  3. PubMed
    https://pubmed.ncbi.nlm.nih.gov

    MOR202, a novel anti-CD38 monoclonal antibody, in patients with ...

    标记:
    Multiple myeloma
    Monoclonal Antibody
    Publish Year:2020
  4. American Society of Hematology
    https://ashpublications.org › ...

    A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in ...

    标记:
    Multiple myeloma
    Monoclonal Antibody
    Publish Year:2016
  5. American Society of Hematology
    https://ashpublications.org › ...

    The Activity of MOR202, a Fully Human Anti-CD38 …

    2012年11月16日 · MOR202, a HuCAL-derived fully human anti-CD38 antibody has proven to be highly effective in preclinical models of multiple myeloma (MM) and is currently evaluated in a phase I/II clinical trial. Having previously …

    标记:
    Multiple myeloma
    Publish Year:2012
  6. ASCO Publications
    https://ascopubs.org › doi

    Fully human antibody MOR202 against CD38 for the treatment of …

    标记:
    Multiple myeloma
    Author:M. Tesar
    Publish Year:2007
  7. 其他用户还问了以下问题
    Is mor202 a safe anti-CD38 antibody?
    MOR202 is a safe HuCAL-derived fully human IgG1 anti-CD38 antibody, with high efficacy in preclinical models of multiple myeloma (MM). This is an open-label, dose-escalation study (3 + 3 design) to evaluate its safety and preliminary efficacy in adult patients (pts) with relapsed or refractory MM.

    A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03…

    ascopubs.org
    Can a monoclonal antibody target CD38 in patients with multiple myeloma?
    To further explore this therapeutic approach, we investigated the safety and activity of MOR202, a novel monoclonal antibody targeting CD38, in patients with multiple myeloma. This is a multicentre, open-label, phase 1–2a trial done at ten hospitals in Germany and Austria.

    MOR202, a novel anti-CD38 monoclonal antibody, in patients with

    thelancet.com
    How safe is mor202 compared to other anti-CD38 antibodies in relapsed multiple myeloma?
    Generally, the MOR202 safety profile was similar to safety profiles reported from studies of other anti-CD38 antibodies in relapsed or refractory multiple myeloma. 11,26–29 However, in contrast to other anti-CD38 antibodies, we observed mainly grade 1–2 infusion-related reactions (overall incidence of 20%), which were limited to the first cycle.

    MOR202, a novel anti-CD38 monoclonal antibody, in patients with

    thelancet.com
    Does mor202 kill NK cells expressing low CD38 levels?
    In contrast, the potential to induce killing of normal NK cells expressing low levels of CD38 was significantly reduced for MOR202 compared with daratumumab and isatuximab (n=6 donors; median of 7% specific killing vs 30% and 37%, respectively). This appeared to be independent of FcγRIIIa receptor polymorphism status.

    MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent T…

    ashpublications.org
    反馈
  8. The Lancet
    https://www.thelancet.com › pdfs › journals › lanhae
    [PDF]

    MOR202, a novel anti-CD38 monoclonal antibody, in patients …

    标记:
    Multiple myeloma
    Monoclonal Antibody
  9. ASCO Publications
    https://ascopubs.org › doi

    A phase I/IIa study of the human anti-CD38 antibody MOR202 …

    标记:
    Multiple myeloma
    Publish Year:2015
  10. I-Mab
    https://www.i-mabbiopharma.com › cn › i-mab-and-morpho...

    天境生物与德国MorphoSys公司联合宣布TJ202/MOR202完成中国 …

  11. 丁香园
    http://yao.dxy.cn › article

    MorphoSys 宣布多发性骨髓瘤药物 MOR202 的 1/2a 期研究数据